FinancialGovernment SolutionsLegalReuters News AgencyRisk Management SolutionsTax & AccountingBlog: Answers OnInnovation @ Thomson Reuters
Directory of sites
Login
Contact
Support
Myanmar
Energy & Environment
Brexit
North Korea
Charged: The Future of Autos
Future of Money
Breakingviews
Healthcare
April 16, 2018 / 6:07 AM / 8 days ago

BRIEF-Herantis Pharma Announces Positive Interim Data From Lymfactin Study

Reuters Staff

1 Min Read

April 16 (Reuters) - HERANTIS PHARMA OYJ:

* REG-HERANTIS PHARMA ANNOUNCES POSITIVE INTERIM DATA FROM LYMFACTIN STUDY IN SECONDARY LYMPHEDEMA

* PHASE 1 STUDY CONTINUES WITH A 12-MONTH FOLLOW-UP ON PATIENTS. Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below

All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.

© 2018 Reuters. All Rights Reserved.